Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Algernon Pharmaceuticals Inc.
C.AGN
Alternate Symbol(s):
AGNPF
Consumer Cyclical
Healthcare
Advertising Agencies
Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N...
-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Company Website
Add To Watchlist
Bullboard (CSE:AGN)
New Post
View:
Posts & Comments
Threaded Posts
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
(83)
•••
biggonads
X
View Profile
View Bullboard History
Post by
biggonads
on Sep 22, 2022 4:44pm
Orphan designation would literally be the biggest catalyst
Imagine if Algernon receives the orphan designation for Ifenprodil. Orphan designation is literally one of the strongest possible catalysts for any biotech stock due to its potential 7-year
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Sep 21, 2022 7:00am
New Press Release - Algernon Pharmaceuticals Announces Receipt of CDN $450K Cash Refund from Australian Research Program
VANCOUVER, British Columbia, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has recently received a cash payment...
read article.
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource
posted Sep 19, 2024 9:00am by
Northstar Gold Corp.
-
|
The MOU grants Hunan Nonferrous the opportunity to explore and develop a near-surface NI43-101 gold mineral resource at Northstar’s 100%-owned Miller Copper-Gold Property, located 18 kilometers southeast of Kirkland Lake, Ontario. This will be achieved by diamond drilling up to 10,000 meters, allowing Hunan Nonferrous to earn a negotiated interest in the resultant NI43-101 gold resource. ...read more
(86)
•••
yopmemama021
X
View Profile
View Bullboard History
Post by
yopmemama021
on Sep 20, 2022 4:18pm
AGN
Yesterday $AGN filed a request for orphan designation with the FDA for Ifenprodil as a treatment for IPF (chronic lung condition) following positive results earlier this month from full
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Sep 19, 2022 7:00am
New Press Release - Algernon Pharmaceuticals Files for Orphan Designation with the U.S. FDA for Ifenprodil as a Treatment of IPF
VANCOUVER, British Columbia, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that it has decided to advance its investigation of NP...
read article.
(36)
•••
Justdosomedd
X
View Profile
View Bullboard History
Post by
Justdosomedd
on Sep 16, 2022 1:51pm
Lots of Potential for the DMT Phase 1 Trial
Algernon has had a lot of recent news/study results come out from the promising chronic cough and IPF study. However, they're also researching drug repurposing for a number of other diseases as
...more
(38)
•••
StockHawk1
X
View Profile
View Bullboard History
Post by
StockHawk1
on Sep 15, 2022 5:29pm
AGN's DMT study for treating stroke
Algernon Pharmaceuticals Inc. (AGN.c AGNPF) received approval to conduct a clinical study on treating stroke with DMT. The first part of AGN's study will try to identify a safe non
...more
(15)
•••
Nice1Bucko
X
View Profile
View Bullboard History
Post by
Nice1Bucko
on Sep 14, 2022 12:33pm
Algernon Pharmaceuticals AGN AGN.CA 💊💊
Algernon Pharmaceuticals is increasing studies and getting closer to having Ifenprodil on the market for treatment of Chronic idiopathic pulmonary fibrosis
(40)
•••
StockDoctor101
X
View Profile
View Bullboard History
Post by
StockDoctor101
on Sep 13, 2022 11:31am
AGN conducting phase 1 study of DMT
AGN announced yesterday that they've received approval to conduct a phase 1 study of an IVF of AP-188 (DMT) for treatment of stroke in the Netherlands from BEBO. While multiple studies have
...more
(38)
•••
StockHawk1
X
View Profile
View Bullboard History
Post by
StockHawk1
on Sep 12, 2022 4:48pm
Breakdown for AGN's latest clinical study approval
Today Algernon Pharmaceuticals Inc. (AGN.c AGNPF) announced that it has received approval to conduct a Phase 1 clinical study of an IVF of DMT for the treatment of stroke. AGN plans to dose the first
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Sep 12, 2022 7:00am
New Press Release - Algernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 DMT Human Stroke Study
VANCOUVER, British Columbia, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that it has received approval to conduct a Phase 1...
read article.
(40)
•••
StockDoctor101
X
View Profile
View Bullboard History
Post by
StockDoctor101
on Sep 09, 2022 11:42am
AGN.c up 77% over the past month
AGN.c announced that they will be the headline sponsor for Wonderland, which is the world-leading academic business gathering for the psychedelic medicine industry. Wonderland will be held from Nov 3
...more
(83)
•••
biggonads
X
View Profile
View Bullboard History
Post by
biggonads
on Sep 08, 2022 2:11pm
AGN CEO discusses positive results in new interview!
ICYMI - Algernon Pharmaceuticals recently reported positive results from their complete data set of its phase 2a study of Ifenprodil for treating idiopathic pulmonary fibrosis (IPF) and chronic cough
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Sep 08, 2022 7:01am
New Press Release - Microdose Announces Algernon Pharmaceuticals as Wonderland's Headline Sponsor
Miami, Florida--(Newsfile Corp. - September 8, 2022) - Microdose Psychedelic Insights, the leading guide to the business of psychedelics, is thrilled to announce Algernon Pharmaceuticals (CSE: AGN) (FSE: AGW0) (OTCQB: AGNPF) ("Algernon") as the official Headline Sponsor for Wonderland, the world...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Sep 08, 2022 7:00am
New Press Release - Algernon Pharmaceuticals Secures Lead Sponsorship of 2022 Wonderland Psychedelic Conference in Miami
VANCOUVER, British Columbia, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage Canadian pharmaceutical development company, is pleased to announce that it will be the Headline Sponsor for...
read article.
(38)
•••
StockHawk1
X
View Profile
View Bullboard History
Post by
StockHawk1
on Sep 07, 2022 2:05pm
AGN.c featured on The Market Herald after sucessful study
The Market Herald recently featured Algernon Pharmaceuticals (AGN.c AGNPF) in 'The Power Play' after the biotech company reported positive drug study results. Its Phase 2a Study evaluating
...more
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
EnviroGold Global Announces Appointment of Chief Operating Officer
Mining Player Sells Off Promising Project for Millions – Here's Where the Cash is Headed